Reversed-phase liquid chromatographic determination of zaleplon in human plasma and its pharmacokinetic application

Analytical Letters

Volumn 39, Issue 9, 2006, Pages 1891-1905

  Foda, Nagwa ^a   Abd Elbary, A ^b   El Gazayerly, O ^b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Bioavailability; Bioequivalence; HPLC determination; Human plasma; Pharmacokinetics; Zaleplon

Indexed keywords

EID: 33745599901     PISSN: 00032719     EISSN: 1532236X     Source Type: Journal    
DOI: 10.1080/00032710600721654     Document Type: Article

References (17)

1. Ancoli-Israel, S., Walsh, J.K., Mangano, R.M., and Fujimori, M. 1999. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Prim. Care Companion J. Clin. Psychiatry., 1 (4): 114-120.
2. Ashton, C.H. 2003. Insomnia and anxiety. In Clinical Pharmacy and Therapeutics, 3rd Ed.; Walker, R. and Edwards, C. (eds.), Churchill Livingstone: UK.
3. Charney, D.S., Mihic, S.J., and Harris, R.A. 2001. Hypnotics and sedatives. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th; Hardman, J.G., Limbird, L.E. and Gilman, A.G. (eds.), McGraw-Hill: USA.
4. Dooley, M. and Plosker, G.L. 2000. Zaleplon: a review of its use in the treatment of insomnia. Drugs, 60 (2): 413-445.
5. Drover, D.R. 2004. Comparative pharmacokinetics and pharmacodynamics of short acting hypnosedatives: zaleplon, zolpidem and zoplicone. Clin.Pharmacokinet., 43 (4): 227-238.
6. Elie, R., Ruther, E., Farr, I., Emielen, G., and Salinas, E. 1999. Sleep latency is shortened during four weeks of treatment with zaleplon, a novel non benzodiazepine hypnotic. J. Clin. Psychiatry, 60 (8): 536-544.
7. Feng, F., Jiang, J., Dai, H., and Wu, J. 2003. Development and validation of a high-performance liquid chromatography-electrospray ionization-mass spectrometry assay for the determination of zaleplon in human plasma. J. Chromatogr Sci., 41 (1): 17-21.
8. Fry, J., Scharf, M., Mangano, R., and Fujimori, M. 2000. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Int. Clin. Psychopharmacol., 15(3): 141-152.
9. Giroud, C., Augsburger, M., Menetrey, A., and Mangin, P. 2003. Determination of zaleplon and zolpidem by liquid chromatograohy-turbo-ionspray mass spectrometry: application to forensic medicine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 789 (1): 131-138.
10. Horstkotter, C., Schepmann, D., and Blaschke, G. 2003. Separation and identification of zaleplon metabolites in human urine using capillary electrohoresis with laser-induced fluorescence detection and liquid chromatography-mass spectrometry. J. Chromatogr. A, 1014 (1-2): 71-81.
11. Lake, B.G., Ball, S.E., Kao, J., Renwick, A.B., Price, R.J., and Scatina, J.A. 2002. Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica, 32 (10): 835-847.
12. Miller, M.M. 2000. Non selective and selective benzodiazepine receptor agonists-where are we today? Sleep, 23 (suppl1): S39-S47.
13. Patat, A., Patty, I., and Hindmarch, I. 2001. Pharmacodynamic profile of zaleplon, a new non-benzodiazepine hypnotic agent. Human Psychopharmacol., 16 (5): 369-392.
14. Rosen, A.S., Fournie, P., Darwish, M., Danjou, P., and Troy, S.M. 1999. Zaleplon pharmacokinetics and absolute bioavailability. Biopharm. Drug Dispos., 20 (3): 171-175.
15. Wagner, J. and Wagner, M.L. 2000. Non benzodiazepines for the treatment of insomnia. Sleep Med. Rev., 4 (6): 551-581.
16. Walsh, J.K., Vogel, G.W., Schart, M., Erman, M., Erwin, C.W., Schweitzer, P.K., Mangano, R.M., and Roth, T. 2000. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med, 1: 41-49.
17. Weitzel, K.W., Wickman, J.M., Augustin, S.G., and Strom, J.G. 2000. Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia. Clin. Ther., 22 (11): 1254-1267.